Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Curis Inc CRIS

Healthcare Biotechnology
Curis, Inc. is a biotechnology company. The Company is focused on the development of emavusertib (CA-4948), an orally available, small molecule inhibitor of Interleukin-1 receptor associated kinase (IRAK4). Emavusertib is undergoing testing in the Phase I/II TakeAim Lymphoma study in patients with relapsed/refractory primary central nervous system lymphoma (PCNSL) in combination with the BTK... see more

Recent & Breaking News (NDAQ:CRIS)

Curis Provides Third Quarter 2024 Business Update

PR Newswire 12 days ago

Curis to Report Third Quarter 2024 Financial and Operating Results and Host Conference Call and Webcast on November 14, 2024

PR Newswire November 7, 2024

Curis Announces $12.1 Million Registered Direct and Concurrent Private Placement

PR Newswire October 29, 2024

Curis Announces the 3rd Annual Symposium on IRAK4 in Cancer

PR Newswire September 23, 2024

Curis to Participate at the Upcoming 2024 Cantor Fitzgerald Global Healthcare Conference

PR Newswire September 17, 2024

Curis to Present at Upcoming Healthcare Conferences in September

PR Newswire September 4, 2024

Curis Provides Second Quarter 2024 Financial and Operating Update

PR Newswire August 1, 2024

Curis to Report Second Quarter 2024 Financial and Operating Results and Host Conference Call and Webcast on August 1, 2024

PR Newswire July 25, 2024

Curis to Present at Upcoming Healthcare Conference in July

PR Newswire July 10, 2024

Curis Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

PR Newswire July 8, 2024

Curis Announces Additional Data from TakeAim Leukemia Study

PR Newswire May 14, 2024

Curis to Present Updated Data from the TakeAim Leukemia Study

PR Newswire May 10, 2024

Curis Provides First Quarter 2024 Business Update

PR Newswire May 7, 2024

Curis to Release First Quarter 2024 Financial Results and Hold Conference Call on May 7, 2024

PR Newswire April 30, 2024

Curis Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

PR Newswire April 5, 2024

Curis to Present at Upcoming Healthcare Conferences in April

PR Newswire April 4, 2024

SHAREHOLDER ALERT: Purcell & Lefkowitz LLP Announces Shareholder Investigation of Curis, Inc. (NASDAQ: CRIS)

PR Newswire April 2, 2024

Curis Provides Fourth Quarter 2023 Business Update

PR Newswire February 8, 2024

Curis to Release Fourth Quarter 2023 Financial Results and Hold Conference Call on February 8, 2024

PR Newswire February 1, 2024

Curis Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

PR Newswire January 5, 2024